Streetbeat News

Analyst Ratings

NIO

NIO shares have declined following a downgrade from Buy to Neutral by B of A Securities.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 6:48 pm

BNTX

BioNTech Inc. (NASDAQ:BNTX) saw a 2.30% drop in its share price to $109.31, despite an 8.87% increase over the past month. The stock has fallen 28.21% over the past year. Investors are examining BioNTech's P/E ratio, which at 9.08 is lower than the Biotechnology industry average of 40.76. This could suggest that BioNTech is undervalued compared to its peers or that investors expect lower future growth. The P/E ratio is a critical metric but should be used alongside other analyses for investment decisions.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:45 pm

POST

Mizuho Securities analyst John J. Baumgartner initiated coverage on Post Holdings Inc (NYSE:POST) with a Buy rating and a $110 price target. Baumgartner highlights POST's strategic acquisitions, alternative structures for enhancing returns, diversified portfolio, and strong cash returns. The company's value-oriented portfolio is seen as well-positioned for consumer economization, with potential for long-term EBITDA growth, especially in the pet category. POST shares saw a slight increase of 0.78% to $93.39.

Portfolio Pulse from Shivani Kumaresan

January 09, 2024 | 6:41 pm

DASH

DoorDash shares have risen following an Outperform rating and $120 price target initiation by BMO Capital.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 6:21 pm

UBER

Uber's stock is experiencing an uptick following BMO Capital's initiation of coverage with an Outperform rating and a price target of $69.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 6:19 pm

EWP

GRFS

Grifols S.A. (NASDAQ:GRFS) experienced a 24% stock price drop after Gotham City Research released a report alleging serious accounting irregularities, including inflated EBITDA, manipulated debt levels, and tunneling transactions. The report suggests Grifols' actual debt may be significantly higher than reported, potentially leading to unsustainable financing costs and insolvency. The iShares MSCI Spain ETF (NYSE:EWP) also declined by 1.9% amid the fallout.

Portfolio Pulse from Piero Cingari

January 09, 2024 | 6:09 pm

IAS

Four financial analysts have recently updated their ratings for Integral Ad Science (NASDAQ:IAS), with three being somewhat bullish and one indifferent. The average 12-month price target is now $17.38, down from $21.83, indicating a 20.38% decrease. Analysts from BMO Capital, Piper Sandler, Morgan Stanley, and Barclays have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Integral Ad Science, a digital ad verification company, has seen a revenue growth of 18.74% over the past three months but struggles with profitability and efficiency, with a net margin of -11.43% and ROE of -1.57%.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:01 pm

HPE

JBLU

JetBlue Airways Corporation (NASDAQ:JBLU) shares fell by over 10% after B of A Securities analyst Andrew Didora downgraded the stock from Neutral to Underperform and lowered the price target from $6 to $3. The company also announced that Joanna Geraghty will succeed Robin Hayes as CEO in February 2024. Other stocks moved significantly in Tuesday's mid-day session, with various gainers and losers across different sectors.

Portfolio Pulse from Avi Kapoor

January 09, 2024 | 6:01 pm

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) has been evaluated by 13 analysts over the last three months, with diverse opinions ranging from bullish to bearish. The average 12-month price target for REGN is $924.23, up 5.8% from the previous target of $873.57. Analysts from firms like Cantor Fitzgerald, Truist Securities, TD Cowen, Jefferies, Deutsche Bank, Piper Sandler, RBC Capital, Morgan Stanley, and Raymond James have provided updates, with some maintaining their ratings and others raising or lowering their price targets. Regeneron is known for its products in various medical fields and has shown strong financial health with a high net margin and ROE, a positive revenue trend, and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:00 pm

RBLX

Roblox (NYSE:RBLX) has been evaluated by 15 analysts over the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target for RBLX is now $44.0, up 18.06% from the previous $37.27, with a range of $26.00 to $55.00. Analysts from firms like BMO Capital, Wells Fargo, and Goldman Sachs have provided various ratings and price target adjustments, reflecting changes in market conditions and company performance. Roblox's financial performance shows strong revenue growth and net margin, but a high debt-to-equity ratio and low ROE.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:00 pm